Avibactam (free acid)

Avibactam (NXL-104) free acid is a covalent and reversible non-β-lactam β-lactamase inhibitor which inhibits β-lactamase TEM-1 and CTX-M-15 with IC50s of 8 nM and 5 nM, respectively[1].

Product Specifications

CAS Number

[1192500-31-4]

Product Name Alternative

NXL-104 (free acid)

UNSPSC

12352005

Target

Antibiotic; Bacterial; Beta-lactamase

Type

Reference compound

Related Pathways

Anti-infection

Applications

Neuroscience-Neuromodulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/Avibactam-free-acid.html

Purity

99.27

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

O=S(ON1[C@]2([H])CC[C@@H](C(N)=O)[N@@](C2)C1=O)(O)=O

Molecular Formula

C7H11N3O6S

Molecular Weight

265.24

References & Citations

[1]Ehmann DE, et al. Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor. Proc Natl Acad Sci U S A. 2012 Jul 17;109 (29) :11663-8.|[2]Livermore DM, et al. Characterization of β-lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline + avibactam (NXL104) . J Antimicrob Chemother. 2012 Jun;67 (6) :1354-8.|[3]Berkhout J, et al. Pharmacokinetics and penetration of ceftazidime and avibactam into epithelial lining fluid in thigh- and lung-infected mice. Antimicrob Agents Chemother. 2015 Apr;59 (4) :2299-304.|[4]Zhang W, et al. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing Klebsiella pneumoniae. Antimicrob Resist Infect Control. 2018 Nov 21;7:142.

Shipping Conditions

Room Temperature

Storage Conditions

-20°C, 3 years; 4°C, 2 years (Powder)

Scientific Category

Reference compound1

Clinical Information

Launched

Citation 01

Antibiotics (Basel) . 2023 Jul 20;12 (7) :1212.|Antibiotics (Basel) . 2024 May 1, 13 (5), 416.|Antimicrob Agents Chemother. 2017 Mar 24;61 (4) . pii: e02260-16.|Antimicrob Agents Chemother. 2018 Dec 21;63 (1) . pii: e01809-18.|Antimicrob Agents Chemother. 2019 Aug 23;63 (9) :e01374-19.|Antimicrob Agents Chemother. 2019 Sep 16;63 (12) :e01515-19.|Antimicrob Agents Chemother. 2020 Feb 21;64 (3) :e02025-19.|Antimicrob Agents Chemother. 2020 Sep 21;64 (10) :e00409-20.|Antimicrob Agents Chemother. 2023 Jul 18;67 (7) :e0033923.|Antimicrob Agents Chemother. 2023 Jun 15;67 (6) :e0160322.|Antimicrob Agents Chemother. 2023 Oct 18;67 (10) :e0030123.|Antimicrob Agents Chemother. 2023 Oct 18;67 (10) :e0052823.|Antimicrob Agents Chemother. 2024 Nov 6;68 (11) :e0077524.|Biomed Res Int. 2018 Jul 2:2018:3579832.|BMC Microbiol. 2020 Jun 29;20 (1) :187.|BMC Microbiol. 2019 Nov 1;19 (1) :240.|Eur J Clin Microbiol Infect Dis. 2025 Feb;44 (2) :277-284.|Eur J Clin Microbiol Infect Dis. 2025 Mar;44 (3) :571-585.|Int J Med Microbiol. 2020 Jul;69 (7) :928-931.|J Antimicrob Chemother. 2017 Jul 1;72 (7) :1930-1936.|J Antimicrob Chemother. 2017 Sep 1;72 (9) :2483-2488.|J Antimicrob Chemother. 2020 Sep 1;75 (9) :2609-2615.|J Antimicrob Chemother. 2024 Jun 3;79 (6) :1309-1312.|J Clin Microbiol. 2023 May 23;61 (5) :e0164722.|Microb Drug Resist. 2020 Apr;26 (4) :334-340.|Microbiol Spectr. 2023 Jun 15;11 (3) :e0069223.|Preprints. 2023 Jun 21.|ACS Infect Dis. 2021 Aug 13;7 (8) :2425-2436.|ACS Infect Dis. 2025 Apr 11;11 (4) :929-939.|Acta Microbiol Immunol Hung. 2021 Jul 29.|Adv Ther (Weinh) . 2024 Jan 12.|Antibiotics (Basel) . 2021 Nov 3;10 (11) :1341.|Antibiotics (Basel) . 2021 Sep 14;10 (9) :1110.|Antibiotics (Basel) . 2022 Sep 20;11 (10) :1280.|Antimicrob Agents Chemother. 2018 Jul 27;62 (8) . pii: e00414-18. |Antimicrob Agents Chemother. 2018 Jul 27;62 (8) . pii: e00433-18.|Antimicrob Agents Chemother. 2018 May 25;62 (6) . pii: e00282-18. |Antimicrob Agents Chemother. 2018 Sep 24;62 (10) . pii: e00873-18.|Antimicrob Agents Chemother. 2022 Jun 21;66 (6) :e0240221.|Antimicrob Agents Chemother. 2023 Feb 16;67 (2) :e0145922.|Antimicrob Agents Chemother. 2025 Apr 14:e0179724.|Antimicrob Agents Chemother. 2025 Mar 5;69 (3) :e0151824.|Antimicrob Agents Chemother. 2025 Mar 5;69 (3) :e0173624. |bioRxiv. 2021 Mar 13.|bioRxiv. 2024 Sep 25:2024.09.25.615047.|Biosens Bioelectron. 2021 Dec 1:193:113526.|Cell Rep. 2024 Nov 9;43 (11) :114962.|Eur J Clin Microbiol Infect Dis. 2025 Sep 29.|Infect Drug Resist. 2020 Aug 18;13:2883-2890.|Infect Drug Resist. 2021 Jun 30;14:2499-2507.|Infect Genet Evol. 2025 Sep:133:105780.|Int J Antimicrob Agents. 2018 Aug;52 (2) :269-271.|Int J Antimicrob Agents. 2024 Jun 24:107256.|Int J Antimicrob Agents. 2024 May 14:107206.|Int J Infect Dis. 2020 Apr;93:252-257. |Int J Med Microbiol. 2021 Oct;70 (10) .|Int J Mol Sci. 2021 Mar 17;22 (6) :3051.|iScience. 2025 Mar 28;28 (5) :112311. |J Antimicrob Chemother. 2021 Feb 11;76 (3) :653-658.|J Antimicrob Chemother. 2021 Jul 15;76 (8) :2071-2078.|J Antimicrob Chemother. 2022 Sep 30;77 (10) :2803-2808.|J Antimicrob Chemother. 2023 Apr 3;78 (4) :983-990.|J Antimicrob Chemother. 2025 Nov 5:dkaf408.|J Antimicrob Chemother. 2025 Oct 27:dkaf388.|J Antimicrob Chemother. 2025 Sep 29:dkaf360.|J Infect Dev Ctries. 2021 Mar 31;15 (3) :404-414.|J Infect Dis. 2019 Jul 2;220 (3) :484-493.|Microbiol Spectr. 2022 Oct 26;10 (5) :e0139022.|Microbiol Spectr. 2022 Oct 26;10 (5) :e0203522.|Microbiol Spectr. 2023 Dec 12;11 (6) :e0304723.|Microbiol Spectr. 2023 Feb 14;11 (1) :e0303822.|Microbiol Spectr. 2024 Oct 3;12 (10) :e0095324.|Microbiol Spectr. 2025 Sep 2;13 (9) :e0019825.|Molecules. 2025 Mar 9;30 (6) :1224.|Nature. 2024 Aug;632 (8026) :893-902.|Open Forum Infect Dis. 2024 Oct 11;11 (11) :ofae611.|PLoS Pathog. 2024 Dec 31;20 (12) :e1012783.|RSC Adv. 2023 Nov 30;13 (49) :34884-34890.|Sci Rep. 2022 Oct 7;12 (1) :16814.|Seoul National University. 2025 Feb.|University of Skovde. 2025.|Int J Infect Dis. 2021 May:106:415-420.|J Clin Microbiol. 2020 Aug 24;58 (9) :e00932-20.